http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP055970-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30ed587317ad9a18467c0752dea305e6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4748 |
| filingDate | 2005-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a6f141df43ec2ca48236ad8ad0f973a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88a9db0380c36bcb7a1e91f43f5c932f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21e1d1c833cf1eecd9555dda680401bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db1ab4521e859147b9c3042e7aca0b4d |
| publicationDate | 2006-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EC-SP055970-A |
| titleOfInvention | USE OF PALONOSETRON FOR THE TREATMENT OF NAUSEA AND POST OPERATIONAL VOMITING |
| abstract | It has been found with surprise that a fairly small dose of palonosetron is effective against NVPO, and that this small dose is effective for almost as long as a patient undergoes a surgical operation usually runs the risk of developing NVPO (usually within 0-36 hours of operation). Therefore, the invention offers in one aspect a complete method for treating or preventing NVPO in a human person, which comprises administering from about 0.025 to about 0.25mg of palonosetron or a pharmaceutically acceptable salt thereof at the time of operation. The method is effective against NVPO caused by various surgical operations and anesthetic compounds, as discussed in more detail below. Another aspect derives from the unexpected long duration of the action of palonosetron, and the ease of the compound to prevent "establishment delayed "of NVPO (that is, that NVPO shows up about 4, 6, 8, 12, or 18 hours after surgery). Therefore, in another aspect the invention offers a method of treatment or prevention of delayed establishment of NVPO which comprises the administration of an effective amount of palonosetron treatment or a pharmaceutically acceptable salt thereof at the time of operation. Another aspect is derived the rapid unexpected establishment of palonosetron after administration, and its use as a rescue medication when NVPO is unexpectedly suffered. Therefore, also in another aspect the invention offers a method of rescuing an NVPO patient comprising the administration of an effective amount of palonosetron treatment or a pharmaceutically acceptable salt thereof shortly after the start of said NVPO. The method will normally be performed in more than about 1, 2, 3, 4, 5 or 6 hours after the operation but within 36 hours after the operation.The amazing power and longer half-life of the palonosetron plasma also cover various clinical needs not covered, including: greater efficacy, lower cost, less side effects and longer duration of action. For this reason, in another aspect the invention offers a method for the treatment or prevention of emesis (whatever the cause) comprising the administration of a single dose of effective treatment of palonosetron or a pharmaceutically acceptable salt thereof during a period of seven days, beginning mainly at the time of the emesis. Emesis can be induced by various medical procedures, including chemotherapy, radiotherapy and surgical operations. Surprisingly it has also been found that palonosetron has an efficacy plateau, which when combined with its safety profile allows to effectively administer a single dose in one range of body weights. Therefore, in another aspect, the invention offers a method for the treatment or prevention of emesis (whatever the cause) comprising administering a defined dose of palonosetron or a pharmaceutically acceptable dose thereof to different patients with different body weights between 50 and 80 kilos of weight, when this defined dose is the same among this range of patients. |
| priorityDate | 2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6337614 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493889 |
Total number of triples: 21.